Status:
UNKNOWN
The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection
Lead Sponsor:
Acibadem University
Collaborating Sponsors:
Acıbadem Labcell
Conditions:
Covid19
Eligibility:
All Genders
18-75 years
Brief Summary
Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient acces...
Detailed Description
The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has s...
Eligibility Criteria
Inclusion
- Are over the age of 60 or-
- Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular illness, hypertension, DM)
- Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia
Exclusion
- Multiple Organ Failure
Key Trial Info
Start Date :
February 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04769245
Start Date
February 18 2021
End Date
June 1 2021
Last Update
February 24 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Acıbadem Labcell Cellular Therapy Laboratories
Istanbul, Turkey (Türkiye), 34758
2
Acibadem Altunizade Hospital
Istanbul, Turkey (Türkiye)